drugset / Trial / NCT07715097
Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
NaSingle-groupOpen-labelPrevention
Summary
The overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.
Timeline
- Start
- 2026-09-30
- Primary completion
- 2028-09-30
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Survivin-targeted DC Cell Injection | Cell therapy | 6 ml | Intravenous |